Investigational drug · Phase 2
TQB3702
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for B-cell Lymphoma, Systemic Lupus Erythematosus.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "TQB3702"
First trial start
2024
Nov 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB3702", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-cell Lymphoma
- Systemic Lupus Erythematosus
Approved drugs for the same conditions: Lupus (SLE) · Hematology and blood cancers · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB3702" as an intervention, largest first.
- A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic MalignancyStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06211751 · 208 participants (planned) · Start Jan 2024 · Primary completion Dec 2025
Drug: TQB3909 tablets; TQB3702 tablets · For: Hematologic Malignancy
Sites: Zhengzhou, China
- Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor SubjectsStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05610202 · 137 participants (planned) · Start Nov 2022 · Primary completion Aug 2024
Drug: TQB3702 tablets · For: Hematologic Malignancy
Sites: Nanchang, China; Jinan, China
- Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)Pivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06859931 · 120 participants (planned) · Start Mar 2025 · Primary completion Dec 2026
Drug: TQB3702 Tablets; TQB3702 Tablets+TQB3702 Placebo and 1 more · For: Systemic Lupus Erythematosus
Sites: Bengbu, China; Hefei, China; Beijing, China · 37 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06566586 · 80 participants (planned) · Start Nov 6, 2024 · Primary completion Mar 2026
Drug: TQB3702 tablets+Chemotherapy regimen · For: B-cell Lymphoma
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 30 sites in all
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult SubjectsStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06448273 · 40 participants (planned) · Start Jul 19, 2024 · Primary completion Oct 2024
Drug: TQB3702 tablets; TQB3702 placebo · For: Systemic Lupus Erythematosus
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for B-cell Lymphoma
- NX-5948bexobrutidegPhase 33 trials
Nurix Therapeutics, Inc. · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Zugocabtagene geleucelCTX112Phase 23 trials
CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.